Prot # CLCI699C2201: A Proof-of Concept, Open-Label, Forced Titration, Multi-Center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients with Cushing's Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date7/22/11 → 7/22/14

Funding

  • Novartis Pharmaceuticals Corporation (Prot # CLCI699C2201)